Breaking News Instant updates and real-time market news.

2021-08-02 05:35:18 ACSAY ACS $5.25 / -0.065 (-1.22%) 05:35 08/02/21 08/02 05:35 08/02/21 05:35	ACS upgraded to Buy on valuation at Kepler Cheuvreux Kepler Cheuvreux analyst Luis Prieto upgraded ACS to Buy from Hold with a price target of EUR 28.25, up from EUR 28. The stock has seen its discount to net asset value widen to more than 40%, Prieto tells investors in a research note. The analyst believes his 25% discount assumption "provides a more than sufficient valuation buffer."

2021-08-02 05:35:18

ACSAY

ACS

$5.25 / -0.065 (-1.22%)

05:35

08/02/21

08/02

05:35

08/02/21

05:35

ACS upgraded to Buy on valuation at Kepler Cheuvreux

Kepler Cheuvreux analyst Luis Prieto upgraded ACS to Buy from Hold with a price target of EUR 28.25, up from EUR 28. The stock has seen its discount to net asset value widen to more than 40%, Prieto tells investors in a research note. The analyst believes his 25% discount assumption "provides a more than sufficient valuation buffer."

OTHER BREAKING NEWS FROM THE FLY

Recommendations	Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald » 07:28 08/12/22 08/12 07:28 08/12/22 07:28 NKTX Nkarta $15.59 / -0.36 (-2.26%) Cantor Fitzgerald analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options NKTX Nkarta $15.59 / -0.36 (-2.26%) 07/25/22 Nkarta promotes Ralph Brandenberger to Chief Technical Officer 04/25/22 Nkarta trading resumes 04/25/22 Nkarta trading halted, volatility trading pause 04/25/22 Nkarta announces preliminary dose finding data for two NK cell programs NKTX Nkarta $15.59 / -0.36 (-2.26%) 07/28/22 Needham Nkarta initiated with a Buy at Needham 07/18/22 SVB Securities Nkarta initiated with an Outperform at SVB Securities 04/26/22 Stifel Nkarta's AML/NHL data 'a positive' for CAR-NK space, says Stifel 04/25/22 Cantor Fitzgerald Nkarta assumed with an Overweight at Cantor Fitzgerald NKTX Nkarta $15.59 / -0.36 (-2.26%) 08/11/22 Nkarta reports Q2 EPS (61c), consensus (60c) 05/12/22 Nkarta reports Q1 EPS (79c), consensus (72c) 03/17/22 Nkarta reports Q4 EPS (69c), consensus (90c) 26 Apr NKTX Nkarta $15.59 / -0.36 (-2.26%) 04/26/22 What You Missed On Wall Street On Tuesday 04/26/22 What You Missed On Wall Street This Morning 04/25/22 Fly Intel: After-Hours Movers 04/25/22 What You Missed On Wall Street On Monday NKTX Nkarta $15.59 / -0.36 (-2.26%) 05/04/22 Nkarta call volume above normal and directionally bullish 04/25/22 Unusually active option classes on open April 25th
Initiation	Mereo BioPharma initiated with an Overweight at Cantor Fitzgerald » 07:27 08/12/22 08/12 07:27 08/12/22 07:27 MREO Mereo BioPharma $1.15 / -0.055 (-4.56%) Cantor Fitzgerald analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals MREO Mereo BioPharma $1.15 / -0.055 (-4.56%) 07/05/22 Mereo BioPharma regains compliance with Nasdaq minimum bid price requirement 06/02/22 Mereo announces portfolio prioritization plan, sees cash runway into late 2024 06/02/22 Mereo BioPharma to present data update for Phase 1b/2 ACTIVATE study 05/26/22 Mereo BioPharma to present updated Phase 1b/2 data on Etigilimab and Nivolumab MREO Mereo BioPharma $1.15 / -0.055 (-4.56%) 06/06/22 Needham Mereo BioPharma price target lowered to $5 from $10 at Needham MREO Mereo BioPharma $1.15 / -0.055 (-4.56%) 06/17/22 AstraZeneca considering bid for Mereo BioPharma, U.K. Times reports
Recommendations	Shattuck Labs price target lowered to $21 from $31 at Needham » 07:26 08/12/22 08/12 07:26 08/12/22 07:26 STTK Shattuck Labs $3.68 / -0.15 (-3.92%) Needham analyst Chad… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly STTK Shattuck Labs $3.68 / -0.15 (-3.92%) 08/11/22 Shattuck Labs expects cash, cash equivalents to fund operations into 2H of 2024 05/12/22 Shattuck Labs sees cash, equivalents funding operations into 2H24 04/08/22 Shattuck Labs presents preclinical SL-9258 data at AACR 03/15/22 Shattuck Labs expects cash to fund operations into 2H24 STTK Shattuck Labs $3.68 / -0.15 (-3.92%) 06/01/22 Citi Shattuck Labs initiated with a Buy at Citi 05/02/22 H.C. Wainwright Shattuck Labs initiated with a Buy at H.C. Wainwright STTK Shattuck Labs $3.68 / -0.15 (-3.92%) 08/11/22 Shattuck Labs reports Q2 EPS (65c), consensus (59c) 05/12/22 Shattuck Labs reports Q1 EPS (58c), consensus (50c) 03/15/22 Shattuck Labs reports Q4 EPS 18c, two est. (43c) STTK Shattuck Labs $3.68 / -0.15 (-3.92%) 06/01/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Downgrade	Lennar downgraded to Neutral from Outperform at Wedbush » 07:25 08/12/22 08/12 07:25 08/12/22 07:25 LEN Lennar $87.78 / +0.47 (+0.54%) Wedbush analyst Jay… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options LEN Lennar $87.78 / +0.47 (+0.54%) 06/26/22 Fly Intel: Top five weekend stock stories 06/21/22 Housing market has cooled as expected, Lennar says 06/21/22 Lennar sees Q3 deliveries 17,000-18,500 03/17/22 Lennar raises FY gross margin view to 27.25%-28% from 27%-27.5% LEN Lennar $87.78 / +0.47 (+0.54%) 06:32 Today Wedbush Lennar downgraded to Neutral from Outperform at Wedbush 07/12/22 JPMorgan JPMorgan 'cautious and less constructive' on homebuilders, downgrades Lennar 07/12/22 JPMorgan Lennar downgraded to Neutral from Overweight at JPMorgan 06/22/22 UBS Lennar price target lowered to $106 from $108 at UBS LEN Lennar $87.78 / +0.47 (+0.54%) 06/21/22 Lennar sees Q3 EPS $4.55-$5.45, consensus $4.78 06/21/22 Lennar reports Q2 EPS $4.49, consensus $3.98 03/17/22 Lennar sees Q2 EPS $3.80-$4.00, consensus $3.75 03/16/22 Lennar sees FY22 deliveries about 68,000 LEN Lennar $87.78 / +0.47 (+0.54%) 06/25/22 Lennar, Nucor among home-building and steel stocks worth a look, Barron's says 04/14/22 Mortgage rates spike to 5% amid post-pandemic price pressures, NY Times says LEN Lennar $87.78 / +0.47 (+0.54%) 06/21/22 What You Missed On Wall Street On Tuesday 06/21/22 What You Missed On Wall Street This Morning 06/21/22 Fly Intel: Pre-market Movers 03/17/22 What You Missed On Wall Street On Thursday LEN Lennar $87.78 / +0.47 (+0.54%) 07/01/22 Early notable gainers among liquid option names on July 1st 06/23/22 Early notable gainers among liquid option names on June 23rd 06/22/22 Early notable gainers among liquid option names on June 22nd 05/25/22 Early notable gainers among liquid option names on May 25th
Hot Stocks	GreenLight Bioscences announces $109M financing » 07:25 08/12/22 08/12 07:25 08/12/22 07:25 GRNA GreenLight Bioscences $4.00 / +0.09 (+2.30%) GreenLight Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News GRNA GreenLight Bioscences $4.00 / +0.09 (+2.30%) 08/01/22 GreenLight, Samsung Biologics complete run for mRNA production partnership 08/01/22 GreenLight Bioscences' COVID-19 vaccine completes first engineering run 07/29/22 GreenLight Bioscences to collaborate on COVID-19 vaccine development with NIH 03/14/22 GreenLight enters into licensing agreement with Serum Institute of India
Hot Stocks	ARC Group says RM2 continues to experience 'record demand' for BLOCKPal pallets » 07:22 08/12/22 08/12 07:22 08/12/22 07:22 ARCW ARC Group $1.00 / + (+0.00%) ARC Group Worldwide… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Hot Stocks	Aptinyx announces NYX-2925 study did not achieve primary endpoint » 07:22 08/12/22 08/12 07:22 08/12/22 07:22 APTX Aptinyx / + Aptinyx announced results… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options APTX Aptinyx / + 04/20/22 Aptinyx says NYX-783 data suggest potential as a treatment for PTSD 04/07/22 Aptinyx trading resumes 04/07/22 Aptinyx trading halted, news pending 04/07/22 Aptinyx announces NYX-2925 study did not achieve primary endpoint APTX Aptinyx / + 05/18/22 Piper Sandler Aptinyx price target lowered to $6 from $10 at Piper Sandler 04/14/22 H.C. Wainwright Aptinyx price target lowered to $2 from $8 at H.C. Wainwright 04/08/22 BMO Capital Aptinyx price target lowered to $6 from $12 at BMO Capital 04/08/22 Truist Aptinyx price target lowered to $5 from $12 at Truist APTX Aptinyx / + 08/04/22 Aptinyx reports Q2 EPS (26c), consensus (28c) 05/12/22 Aptinyx reports Q1 EPS (29c), consensus (30c) 03/23/22 Aptinyx reports Q4 EPS (29c), consensus (35c) APTX Aptinyx / + 03/23/22 Aptinyx options imply 6.9% move in share price post-earnings
Hot Stocks	Unity: UBX1325 injection led to clinically meaningful improvement in mean BCVA » 07:20 08/12/22 08/12 07:20 08/12/22 07:20 UBX Unity Biotechnology / + UNITY Biotechnology… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings UBX Unity Biotechnology / + 07:17 Today Unity Biotechnology announces anticipated milestones 07:17 Today Unity Biotechnology expects cash to fund operations through 1Q23 05/26/22 Unity Biotechnology appoints Michael Samar to board of directors 05/10/22 Unity Biotechnology announces upcoming milestones UBX Unity Biotechnology / + 05/17/22 Citi Unity Biotechnology price target lowered to $5 from $6 at Citi 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy from Neutral at Roth Capital 12/15/21 Wedbush Wedbush bullish on Unity Biotechnology, initiates with an Outperform UBX Unity Biotechnology / + 07:16 Today Unity Biotechnology reports Q2 EPS (19c) vs. (32c) last year 05/10/22 Unity Biotechnology reports Q1 EPS (28c), consensus (26c) 03/15/22 Unity Biotechnology reports Q4 EPS (18), consensus (38c)
Downgrade	Diebold downgraded to Underweight from Neutral at JPMorgan » 07:20 08/12/22 08/12 07:20 08/12/22 07:20 DBD Diebold $4.46 / -0.13 (-2.83%) JPMorgan analyst Paul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly DBD Diebold $4.46 / -0.13 (-2.83%) 07/08/22 Diebold rises 23.3% 05/10/22 Diebold expects to see cost savings of $150M in the next 12-18 months 03/17/22 Diebold: Shipments, sales into Russia suspended since start of Ukraine crisis DBD Diebold $4.46 / -0.13 (-2.83%) 07/08/22 Wedbush Wedbush upgrades Diebold, sees sales and earnings positioned to improve 07/08/22 Wedbush Diebold upgraded to Outperform from Neutral at Wedbush 05/10/22 JPMorgan Diebold downgraded to Neutral at JPMorgan after 'material' guidance cut 05/10/22 JPMorgan Diebold downgraded to Neutral from Overweight at JPMorgan DBD Diebold $4.46 / -0.13 (-2.83%) 08/02/22 Diebold lowers FY22 revenue view to $3.55B-$3.75B from $3.7B-$3.9B 08/02/22 Diebold reports Q2 non-GAAP EPS 38c, consensus (14c) 05/10/22 Diebold lowers FY22 revenue view to $3.7B-$3.9B from $4.0B-$4.2B 05/10/22 Diebold reports Q1 non-GAAP EPS ($1.61), consensus (21c) DBD Diebold $4.46 / -0.13 (-2.83%) 07/08/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Downgrade	Plexus downgraded to Underweight from Neutral at JPMorgan » 07:20 08/12/22 08/12 07:20 08/12/22 07:20 PLXS Plexus $95.69 / +0.88 (+0.93%) JPMorgan analyst Paul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events PLXS Plexus $95.69 / +0.88 (+0.93%) 08/08/22 Plexus opens manufacturing facility in Bangkok, Thailand PLXS Plexus $95.69 / +0.88 (+0.93%) 07/29/22 Needham Plexus price target raised to $105 from $93 at Needham 07/27/22 Benchmark Plexus initiated with a Buy at Benchmark 06/07/22 Raymond James Plexus upgraded to Outperform from Market Perform at Raymond James 01/28/22 Needham Plexus price target lowered to $90 from $95 at Needham PLXS Plexus $95.69 / +0.88 (+0.93%) 07/27/22 Plexus sees Q4 GAAP EPS $1.19-$1.35, consensus $1.10 07/27/22 Plexus reports Q3 adjusted EPS $1.33, consensus $1.10 04/27/22 Plexus reports Q2 EPS 95c, consensus 99c 03/07/22 Plexus reaffirms Q2 EPS guidance 76c-92c, consensus 99c PLXS Plexus $95.69 / +0.88 (+0.93%) 07/27/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/07/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/24/22 Plexus

Downgrade	Cognex downgraded to Underweight from Neutral at JPMorgan » 07:19 08/12/22 08/12 07:19 08/12/22 07:19 CGNX Cognex $48.48 / +0.54 (+1.13%) JPMorgan analyst Paul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly CGNX Cognex $48.48 / +0.54 (+1.13%) 06/09/22 Cognex discloses fire at primary manufacturing facility in Indonesia 03/03/22 Cognex authorizes up to $500M stock buyback program CGNX Cognex $48.48 / +0.54 (+1.13%) 08/03/22 Needham Cognex price target lowered to $50 from $60 at Needham 08/03/22 Cowen Cognex price target lowered to $55 from $75 at Cowen 08/03/22 Stephens Cognex downgraded to Equal Weight at Stephens on logistics demand deteriorating 08/03/22 Stephens Cognex downgraded to Equal Weight from Overweight at Stephens CGNX Cognex $48.48 / +0.54 (+1.13%) 08/02/22 Cognex sees Q3 revenue $160M-$180M, consensus $290.25M 08/02/22 Cognex reports Q2 adjusted EPS 41c, consensus 41c 05/05/22 Cognex sees Q2 revenue $265M-$285M, consensus $292.72M 05/05/22 Cognex reports Q1 EPS 42c, consensus 38c CGNX Cognex $48.48 / +0.54 (+1.13%) 08/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/02/22 Fly Intel: After-Hours Movers 02/17/22 Fly Intel: After-Hours Movers
Recommendations	Six Flags price target lowered to $28 from $35 at Stifel » 07:18 08/12/22 08/12 07:18 08/12/22 07:18 SIX Six Flags $21.12 / -4.685 (-18.16%) Stifel analyst Steven… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 Six Flags falls -22.5% 08/11/22 Six Flags falls -21.5% 08/11/22 Six Flags falls -18.1% 08/11/22 Six Flags reports Q2 attendance 6.7M vs. 8.5M a year ago, down 22% SIX Six Flags $21.12 / -4.685 (-18.16%) 05:44 Today KeyBanc Six Flags downgraded to Sector Weight at KeyBanc after 'indefensible' Q2 08/11/22 KeyBanc Six Flags downgraded to Sector Weight from Overweight at KeyBanc 07/08/22 Citi Six Flags downgraded to Neutral from Buy at Citi 06/24/22 Stifel Six Flags price target lowered to $35 from $52 at Stifel SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 Six Flags reports Q2 EPS 53c, consensus $1.02 08/10/22 Notable companies reporting before tomorrow's open 08/10/22 Notable companies reporting before tomorrow's open 05/12/22 Six Flags reports Q1 EPS (76c), consensus ($1.04) SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 What You Missed On Wall Street On Thursday 08/11/22 What You Missed On Wall Street This Morning 08/11/22 Fly Intel: Pre-market Movers 07/21/22 Fly Intel: After-Hours Movers
Hot Stocks	Unity Biotechnology announces anticipated milestones » 07:17 08/12/22 08/12 07:17 08/12/22 07:17 UBX Unity Biotechnology / + UBX1325 24-week safety… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings UBX Unity Biotechnology / + 07:17 Today Unity Biotechnology expects cash to fund operations through 1Q23 05/26/22 Unity Biotechnology appoints Michael Samar to board of directors 05/10/22 Unity Biotechnology announces upcoming milestones 05/05/22 Unity Biotechnology presents on UBX1325 at ARVO 2022 UBX Unity Biotechnology / + 05/17/22 Citi Unity Biotechnology price target lowered to $5 from $6 at Citi 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy from Neutral at Roth Capital 12/15/21 Wedbush Wedbush bullish on Unity Biotechnology, initiates with an Outperform UBX Unity Biotechnology / + 07:16 Today Unity Biotechnology reports Q2 EPS (19c) vs. (32c) last year 05/10/22 Unity Biotechnology reports Q1 EPS (28c), consensus (26c) 03/15/22 Unity Biotechnology reports Q4 EPS (18), consensus (38c)
Recommendations	Toast price target raised to $25 from $18 at KeyBanc » 07:17 08/12/22 08/12 07:17 08/12/22 07:17 TOST Toast $18.12 / -0.33 (-1.79%) KeyBanc analyst Josh Beck… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Toast up 9% to $19.80 after smaller than expected Q2 loss, raised guidance 07/26/22 Cathie Wood's ARK Investment bought 113K shares of Toast today 07/07/22 Toast acquires employee scheduling, communication solution Sling, no terms 05/13/22 Toast rises 15.2% TOST Toast $18.12 / -0.33 (-1.79%) 05/17/22 Mizuho Toast price target lowered to $18 from $19 at Mizuho 05/13/22 Needham Toast price target lowered to $21 from $38 at Needham 05/13/22 Canaccord Toast price target lowered to $25 from $34 at Canaccord 05/09/22 Mizuho Toast price target lowered to $19 from $23 at Mizuho TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Toast raises FY22 revenue view to $2.62B-$2.66B, consensus $2.54B 08/11/22 Toast sees Q3 revenue $700M-$730M, consensus $665.08M 08/11/22 Toast reports Q2 EPS (11c) vs (64c) last year 08/11/22 Notable companies reporting after market close 22 Sep TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Fly Intel: After-Hours Movers 05/13/22 What You Missed On Wall Street On Friday 05/13/22 What You Missed On Wall Street This Morning 05/13/22 Fly Intel: Pre-market Movers TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Toast Inc options imply 11.3% move in share price post-earnings 05/12/22 Toast Inc options imply 21.6% move in share price post-earnings 03/04/22 Toast Inc put volume heavy and directionally bearish 02/15/22 Toast Inc options imply 15.0% move in share price post-earnings
Hot Stocks	PLx Pharma announces survey data on VAZALORE 81 mg » 07:17 08/12/22 08/12 07:17 08/12/22 07:17 PLXP PLx Pharma $2.59 / +0.015 (+0.58%) PLx Pharma, with its lead… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events PLXP PLx Pharma $2.59 / +0.015 (+0.58%) 05/20/22 PLx Pharma showcases VAZALORE at SCAI annual meeting PLXP PLx Pharma $2.59 / +0.015 (+0.58%) 03/15/22 BWS Financial BWS drops coverage of PLx Pharma, says off Amazon again 12/07/21 Raymond James Raymond James upgrades PLx Pharma on 'compelling entry point' 12/07/21 Raymond James PLx Pharma upgraded to Outperform from Market Perform at Raymond James 11/12/21 JMP Securities PLx Pharma reported strong quarter for Vazalore, says JMP Securities PLXP PLx Pharma $2.59 / +0.015 (+0.58%) 06:55 Today PLx Pharma reports Q2 EPS (52c), consensus (56c) 05/13/22 PLx Pharma reports Q1 non-GAAP EPS (66c), consensus (72c) 03/11/22 PLx Pharma reports Q4 adjusted EPS (73c), consensus (71c) 08:30 Today PLx Pharma - PLXP
Hot Stocks	Unity Biotechnology expects cash to fund operations through 1Q23 » 07:17 08/12/22 08/12 07:17 08/12/22 07:17 UBX Unity Biotechnology / + Cash, cash equivalents… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings UBX Unity Biotechnology / + 05/26/22 Unity Biotechnology appoints Michael Samar to board of directors 05/10/22 Unity Biotechnology announces upcoming milestones 05/05/22 Unity Biotechnology presents on UBX1325 at ARVO 2022 04/28/22 Allogene Therapeutics appoints Lundeen as Chief People Officer UBX Unity Biotechnology / + 05/17/22 Citi Unity Biotechnology price target lowered to $5 from $6 at Citi 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy from Neutral at Roth Capital 12/15/21 Wedbush Wedbush bullish on Unity Biotechnology, initiates with an Outperform UBX Unity Biotechnology / + 07:16 Today Unity Biotechnology reports Q2 EPS (19c) vs. (32c) last year 05/10/22 Unity Biotechnology reports Q1 EPS (28c), consensus (26c) 03/15/22 Unity Biotechnology reports Q4 EPS (18), consensus (38c)
Recommendations	Illumina price target lowered to $300 from $480 at Stifel » 07:16 08/12/22 08/12 07:16 08/12/22 07:16 ILMN Illumina $227.64 / +0.44 (+0.19%) Stifel analyst Daniel… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options ILMN Illumina $227.64 / +0.44 (+0.19%) 08/11/22 Illumina cuts FY22 core Illumina revenue growth view to 3.5%-4.5% 08/11/22 Illumina drops 22% to $177 after Q2 results miss estimates, FY22 guidance cut 06/09/22 Illumina drops 6% to $210.00 after departure of CFO 06/09/22 Illumina CFO Sam Samad to depart, Joydeep Goswami named interim CFO ILMN Illumina $227.64 / +0.44 (+0.19%) 06:59 Today Citi Illumina price target lowered to $200 from $220 at Citi 06:36 Today Baird Illumina price target lowered to $215 from $306 at Baird 08/11/22 Piper Sandler Illumina miss 'surprising' given backlog, says Piper Sandler 07/14/22 Canaccord Illumina merger challenge not reflection of merits, says Canaccord ILMN Illumina $227.64 / +0.44 (+0.19%) 08/11/22 Illumina cuts FY22 adjusted EPS view to $2.75-$2.90 from $4.00-$4.20 08/11/22 Illumina reports Q2 adjusted EPS 57c, consensus 65c 08/11/22 Notable companies reporting after market close 05/05/22 Illumina sees FY22 adjusted EPS $4.00-$4.20, consensus $4.15 ILMN Illumina $227.64 / +0.44 (+0.19%) 07/27/22 Illumina's Grail deal likely to be blocked by EU regulators, Reuters reports 07/13/22 Illumina lost bid to block EU watchdog review of Grail deal, Bloomberg reports ILMN Illumina $227.64 / +0.44 (+0.19%) 08/11/22 Fly Intel: After-Hours Movers 07/13/22 What You Missed On Wall Street On Wednesday 07/13/22 What You Missed On Wall Street This Morning 06/10/22 What You Missed On Wall Street On Friday 09/10/22 ESMO Congress 2022 ILMN Illumina $227.64 / +0.44 (+0.19%) 08/11/22 Illumina options imply 6.5% move in share price post-earnings 06/13/22 Illumina put buyer realizes 25% same-day gains 05/18/22 Early notable gainers among liquid option names on May 18th
Earnings	Unity Biotechnology reports Q2 EPS (19c) vs. (32c) last year » 07:16 08/12/22 08/12 07:16 08/12/22 07:16 UBX Unity Biotechnology / + Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings UBX Unity Biotechnology / + 05/26/22 Unity Biotechnology appoints Michael Samar to board of directors 05/10/22 Unity Biotechnology announces upcoming milestones 05/05/22 Unity Biotechnology presents on UBX1325 at ARVO 2022 04/28/22 Allogene Therapeutics appoints Lundeen as Chief People Officer UBX Unity Biotechnology / + 05/17/22 Citi Unity Biotechnology price target lowered to $5 from $6 at Citi 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy from Neutral at Roth Capital 12/15/21 Wedbush Wedbush bullish on Unity Biotechnology, initiates with an Outperform UBX Unity Biotechnology / + 05/10/22 Unity Biotechnology reports Q1 EPS (28c), consensus (26c) 03/15/22 Unity Biotechnology reports Q4 EPS (18), consensus (38c)
Recommendations	CS Disco price target lowered to $30 from $40 at Stifel » 07:15 08/12/22 08/12 07:15 08/12/22 07:15 LAW CS Disco $28.96 / +0.39 (+1.37%) Stifel analyst J. Parker… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly LAW CS Disco $28.96 / +0.39 (+1.37%) 06/06/22 DISCO appoints Tom Furr as CMO 06/01/22 CS Disco falls -10.8% 04/28/22 DISCO appoints Jignasha Amin Grooms as CHRO LAW CS Disco $28.96 / +0.39 (+1.37%) 06:15 Today BofA CS Disco downgraded to Neutral from Buy at BofA 06:05 Today Canaccord CS Disco downgraded to Hold from Buy at Canaccord 05:40 Today Cowen Cowen cuts CS Disco to Market Perform as momentum hits 'big snag' 05:35 Today Cowen CS Disco downgraded to Market Perform from Outperform at Cowen LAW CS Disco $28.96 / +0.39 (+1.37%) 08/11/22 CS Disco cuts FY22 revenue view to $132M-$136M from $149M-$153M 08/11/22 CS Disco sees Q3 revenue $32M-$34M, consensus $38.29M 08/11/22 CS Disco reports Q2 adjusted (23c), consensus (27c) 05/12/22 CS Disco sees Q2 revenue $32M-$34M, consensus $34.02M 15 Sep LAW CS Disco $28.96 / +0.39 (+1.37%) 08/11/22 Fly Intel: After-Hours Movers 05/12/22 Fly Intel: After-Hours Movers
Earnings	Real Good Food raises FY22 revenue $155M-$160M from $150M-$160M » 07:15 08/12/22 08/12 07:15 08/12/22 07:15 RGF Real Good Food $6.93 / -0.11 (-1.56%) FY22 revenue consensus… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events RGF Real Good Food $6.93 / -0.11 (-1.56%) 08/09/22 Real Good Food Company Inc trading resumes 08/09/22 Real Good Food Company Inc trading halted, volatility trading pause 07/06/22 Real Good Food launches Real Good Foods Perks Program 06/07/22 Real Good Food announces launch of chicken enchiladas in Sam's Club RGF Real Good Food $6.93 / -0.11 (-1.56%) 03/08/22 Roth Capital Real Good Food initiated with a Buy at Roth Capital 11/30/21 Fly Intel: Top five analyst initiations 11/30/21 Jefferies Jefferies starts Real Good Food at Buy, sees 75% upside in 12 months 11/30/21 Truist Real Good Food initiated with a Buy at Truist RGF Real Good Food $6.93 / -0.11 (-1.56%) 07:14 Today Real Good Food reports Q2 revenue $30.809M, consensus $32.12M 05/13/22 Real Good Food sees FY22 revenue $150M-$160M, consensus $143.65M 05/13/22 Real Good Food reports Q1 revenue $37.6M, consensus $32.47M 03/11/22 Real Good Food sees 2022 revenue $140M-$150M, consensus $120.57M 05 Nov 08:30 Today Real Good Food - RGF

General news	Market Update: » 07:15 08/12/22 08/12 07:15 08/12/22 07:15 $ECON Economic Data / + Market Update: Stock… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly $ECON Economic Data / + 06/22/22 President Biden calls on Congress to suspend federal gas tax 05/19/22 Could crypto crash be good for U.S. economy? Probably. 05/12/22 Miller calls out Taylor Morrison, GM as names that may work in this environment 04/21/22 Powell says 50 basis point hike on table for May meeting $ECON Economic Data / + $ECON Economic Data / + 06/14/22 Ackman says 100 point hike tomorrow 'would be better' than 75 $ECON Economic Data / + 07/26/22 Ackman says biggest risk to economy is inflation, not higher rates 06/17/22 White House, Congress in talks over bill to fight inflation, Bloomberg says 06/13/22 Fed more likely to consider 0.75 point hike given recent data, WSJ says 05/10/22 Tepper says covered Nasdaq short, CNBC reports $ECON Economic Data / + 07/27/22 What You Missed On Wall Street On Wednesday 07/21/22 What You Missed On Wall Street On Thursday 07/21/22 What You Missed On Wall Street This Morning 07/06/22 What You Missed On Wall Street On Wednesday
Earnings	Venus Concept sees 2022 revenue $110M-$113M, consensus $126.82M » 07:14 08/12/22 08/12 07:14 08/12/22 07:14 VERO Venus Concept / + The Company now expects… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VERO Venus Concept / + 04/25/22 Venus Concept announces first patient treatment in study of Aime 03/31/22 Venus Concept submits FDA 510(k) for Aime robotic technology VERO Venus Concept / + 06/24/22 BTIG Venus Concept price target lowered to $5.50 from $7.00 at BTIG 11/12/21 Stifel Venus Concept price target trimmed to $2 at Stifel after Q3 miss VERO Venus Concept / + 07:14 Today Venus Concept reports Q2 EPS (16c), consensus (7c) 03/28/22 Venus Concept sees 2022 revenue $126M-$130M, consensus $125.9M 03/28/22 Venus Concept reports Q4 EPS (8c), consensus (10c) 09/29/22 7th Annual Healthcare Conference 08:00 Today Venus Concept - VERO
Earnings	Venus Concept reports Q2 EPS (16c), consensus (7c) » 07:14 08/12/22 08/12 07:14 08/12/22 07:14 VERO Venus Concept / + Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VERO Venus Concept / + 04/25/22 Venus Concept announces first patient treatment in study of Aime 03/31/22 Venus Concept submits FDA 510(k) for Aime robotic technology VERO Venus Concept / + 06/24/22 BTIG Venus Concept price target lowered to $5.50 from $7.00 at BTIG 11/12/21 Stifel Venus Concept price target trimmed to $2 at Stifel after Q3 miss VERO Venus Concept / + 03/28/22 Venus Concept sees 2022 revenue $126M-$130M, consensus $125.9M 03/28/22 Venus Concept reports Q4 EPS (8c), consensus (10c) 09/29/22 7th Annual Healthcare Conference 08:00 Today Venus Concept - VERO
Downgrade	Cellebrite downgraded to Market Perform at William Blair after guidance cut » 07:14 08/12/22 08/12 07:14 08/12/22 07:14 CLBT Cellebrite $5.28 / -0.4 (-7.04%) William Blair analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly CLBT Cellebrite $5.28 / -0.4 (-7.04%) 07/05/22 Cellebrite and Chainalysis launch partnership 06/30/22 Cellebrite announces availability of Cellebrite Physcial Analyzer Ultra Series 05/05/22 Cellebrite announces upcoming release of Cellebrite Premium 04/06/22 Cellebrite announces national police force of EMEA expanded partnership CLBT Cellebrite $5.28 / -0.4 (-7.04%) 06:06 Today William Blair Cellebrite downgraded to Market Perform from Outperform at William Blair 05/16/22 Cowen Cellebrite price target lowered to $13 from $17 at Cowen 05/13/22 Deutsche Bank Cellebrite price target lowered to $10 from $11 at Deutsche Bank 02/24/22 JPMorgan Cellebrite initiated with an Overweight at JPMorgan CLBT Cellebrite $5.28 / -0.4 (-7.04%) 08/11/22 Cellebrite reports Q2 adjusted EPS 0c, consensus 3c 08/11/22 Cellebrite lowers FY22 revenue to $270M-$285M from $285M-$300M 05/12/22 Cellebrite sees FY22 revenue $285M-$300M, consensus $292.06M 05/12/22 Cellebrite reports Q1 adjusted EPS 1c, consensus 2c CLBT Cellebrite $5.28 / -0.4 (-7.04%) 02/24/22 What You Missed On Wall Street On Thursday 02/24/22 What You Missed On Wall Street This Morning 02/24/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Earnings	Real Good Food reports Q2 revenue $30.809M, consensus $32.12M » 07:14 08/12/22 08/12 07:14 08/12/22 07:14 RGF Real Good Food $6.93 / -0.11 (-1.56%) "I am pleased with… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events RGF Real Good Food $6.93 / -0.11 (-1.56%) 08/09/22 Real Good Food Company Inc trading resumes 08/09/22 Real Good Food Company Inc trading halted, volatility trading pause 07/06/22 Real Good Food launches Real Good Foods Perks Program 06/07/22 Real Good Food announces launch of chicken enchiladas in Sam's Club RGF Real Good Food $6.93 / -0.11 (-1.56%) 03/08/22 Roth Capital Real Good Food initiated with a Buy at Roth Capital 11/30/21 Fly Intel: Top five analyst initiations 11/30/21 Jefferies Jefferies starts Real Good Food at Buy, sees 75% upside in 12 months 11/30/21 Truist Real Good Food initiated with a Buy at Truist RGF Real Good Food $6.93 / -0.11 (-1.56%) 05/13/22 Real Good Food sees FY22 revenue $150M-$160M, consensus $143.65M 05/13/22 Real Good Food reports Q1 revenue $37.6M, consensus $32.47M 03/11/22 Real Good Food sees 2022 revenue $140M-$150M, consensus $120.57M 03/11/22 Real Good Food sees Q1 revenue $33M-$35M, consensus $27.33M 05 Nov 08:30 Today Real Good Food - RGF

Events

Earnings calls, analyst events, roadshows and more

GTEC
Today at 08:00

Greenland Technologies - GTEC Conference Calls
VERO
Today at 08:00

Venus Concept - VERO Conference Calls
EVK
Today at 08:00

Ever-Glory - EVK Conference Calls
CMMB
Today at 08:00

Chemomab Therapeutics - CMMB Conference Calls
HUMA
Today at 08:00

Humacyte - HUMA Conference Calls
CAAS
Today at 08:00

China Automotive - CAAS Conference Calls
CASI
Today at 08:00

Casi Pharmaceuticals - CASI Conference Calls
Today at 08:30

Import Prices Y/Y: July 2022 Government Event
Today at 08:30

Export Prices M/M: July 2022 Government Event
Today at 08:30

Export Prices Y/Y: July 2022 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	AYTU X AYTU Aytu BioPharma Spot Secondary Managers: Cantor Fitzgerald & Canaccord Priced at: $0.43 21.5M Shares BRBR X BRBR BellRing Brands Spot Secondary Managers: JPMorgan, Barclays, Citi, Goldman Sachs & Morgan Stanley Priced at: $23.50 14.8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDNA X MDNA Medicenna Therapeutics Spot Secondary Managers: Guggenheim, Bloom Burton Securities Priced at: $1.50 13.333M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NUZE X NUZE NuZee Spot Secondary Managers: Maxim Priced at: $0.82 4.2M Shares PFLT X PFLT PennantPark Floating Rate Spot Secondary Managers: Morgan Stanley, Goldman Sachs, JPMorgan, Keefe Bruyette, RBC Capital & Truist Priced at: $12.40 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan, Jefferies Priced at: $215.00 3.49M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MIRM X MIRM Mirum Pharmaceuticals Spot Secondary Managers: JPMorgan, SVB Securities & Evercore ISI, Raymond James Priced at: $23.00 3.48M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TDW X TDW Tidewater Spot Secondary Managers: Morgan Stanley Priced at: $17.85 3.52M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	ATNX X ATNX Athenex Secondary Managers: SVB Securities Priced at: $.75 35.3M Shares CINC X CINC CinCor Pharma Secondary Managers: Goldman Sachs, Morgan Stanley, Jefferies & Piper Sandler Priced at: $30.00 7.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EVTC X EVTC Evertec Secondary Managers: JPMorgan Priced at: $32.00 6.26M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LXU X LXU LSB Industries Secondary Managers: Goldman Sachs & UBS, Deutsche Bank, Jefferies, Piper Sandler, RBC Capital, BNP Paribas, Stifel Priced at: $13.00 13.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SOVO X SOVO Sovos Brands Secondary Managers: JPMorgan & Goldman Sachs, BofA, Credit Suisse, Barclays, UBS, Cowen, Piper Sandler, Stifel, William Blair, Telsey Advisory, Drexel Hamilton, Loop Capital Priced at: $14.00 8.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRNA X VRNA Verona Pharma Secondary Managers: Jefferies, Piper Sandler & Truist Priced at: $10.50 12.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNL X BNL Broadstone Net Lease Spot Secondary Managers: Goldman Sachs, BMO Capital, JPMorgan & Truist Priced at: $21.35 13M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KIDS X KIDS OrthoPediatrics Spot Secondary Managers: Piper Sandler & Stifel Priced at: $55.00 750K Shares MAIN X MAIN Main Street Spot Secondary Managers: RBC Capital, UBS & Wells Fargo Priced at: $42.85 1.17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	FRZA X FRZA Forza X1 IPO Managers: ThinkEquity Priced at: $5.00 3M Shares REBN X REBN Reborn Coffee IPO Managers: EF Hutton Priced at: $5.00 1.44M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TGL X TGL Treasure Global IPO Managers: EF Hutton Priced at: $4.00 2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERE X CERE Cerevel Therapeutics Secondary Managers: Morgan Stanley, Goldman Sachs, Jefferies & Evercore ISI, Loop Capital, Seibert Williams Priced at: $35.00 7.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INAB X INAB In8bio Secondary Managers: H.C. Wainwright Priced at: $1.90 5.39M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PTLO X PTLO Portillo's Secondary Managers: Jefferies & Morgan Stanley, BofA, Piper Sandler Priced at: $23.75 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INSP X INSP Inspire Medical Spot Secondary Managers: Goldman Sachs Priced at: $215.00 1M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	BIAF X BIAF Bioaffinity Technologies IPO Managers: WallachBeth $6.00-6.25 1.285M Shares
Wed	No deals
Thurs	RANI X RANI Rani Therapeutics Secondary Managers: BofA, Cantor Fitzgerald & UBS, BTIG, H.C. Wainwright $ Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERT X CERT Certara Spot Secondary Managers: Morgan Stanley $17.75-18.50 7M Shares
Fri	No deals

View All Syndicate Announcements »

ACS upgraded to Buy on valuation at Kepler Cheuvreux

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access